It is made available under a CC-BY-NC-ND 4.0 International license .

1	Visceral Leishmaniasis-HIV coinfection as a predictor of increased leishmania transmission at the
2	<u>village level in Bihar, India.</u>
3	
4	Authors: Kristien Cloots, MD ^{*1[∞]} , Pia Marino, MD ^{*1,2} , Sakib Burza, PhD ³ , Naresh Gill,
5	MD ⁴ , Marleen Boelaert, PhD ¹ , Epco Hasker, PhD ¹
6	
7	¹ Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
8	² Erasmus Mundus Joint Master Degree Infectious Diseases & One Health Programme
9	³ Médecins Sans Frontières, New Delhi, India
10	⁴ National Vector Borne Disease Control Programme, India
11	
12	[∞] Corresponding author
13	*These authors contributed equally to this work
14	
15	
16	ABSIKAUI
17	Background : Visceral leishmaniasis (VL) is on the verge of being eliminated as a public health

problem in the Indian subcontinent. Although Post-kala-azar dermal leishmaniasis (PKDL) is recognized as an important reservoir of transmission, we hypothesized that patients with VL coinfected with Human Immunodeficiency Virus (HIV) may also be important reservoirs of sustained leishmania transmission. We therefore investigated to what extent cases of PKDL or VL-HIV are associated with VL incidence at the village level in Bihar, India.

Methods : VL, VL-HIV, and PKDL case data from six districts within the highly VL-endemic
 state of Bihar, India were collected through the Kala-Azar Management Information System for
 the years 2014 – 2019. Multivariate analysis was done using negative binomial regression
 controlling for year as a fixed effect and block (subdistrict) as a random effect.

27

Findings : Presence of VL-HIV and PKDL cases were both associated with a more than twofold increase in VL incidence at village level, with Incidence Rate Ratios (IRR) of 2.16 (95% CI 1.81 -2.58) and 2.37 (95% CI 2.01 – 2.81) for VL-HIV and PKDL cases respectively. A sensitivity analysis showed the strength of the association to be similar in each of the six included subdistricts.

33

34 **Conclusions :** These findings indicate the importance of VL-HIV patients as infectious 35 reservoirs, and suggest that they represent a threat equivalent to PKDL patients towards the VL 36 elimination initiative on the Indian subcontinent, therefore warranting a similar focus.

It is made available under a CC-BY-NC-ND 4.0 International license .

38 CONTRIBUTION TO THE FIELD

Visceral leishmaniasis (VL) - also called kala azar on the Indian subcontinent - is a parasitic disease which is fatal if not treated timely. Since the elimination initiative was launched in 2005 in the Indian subcontinent, the number of cases has come down drastically in this region. However, with the regional incidence of VL decreasing, understanding the role of potentially highly infectious subgroups in maintaining refractory Leishmania transmission is becoming increasingly important. Patients with Post-Kala-Azar Dermal Leishmaniasis (PKDL) are recognized as an important reservoir of transmission. We hypothesized that VL patients coinfected with Human Immunodeficiency Virus (HIV) may also be important reservoirs of sustained leishmania transmission. In this study, we found that the presence of VL-HIV and PKDL patients are both associated with a twofold increase incidence of VL at village level, suggesting they are equally important reservoirs for leishmania transmission. Our paper suggests that VL-HIV patients pose a threat equivalent to PKDL patients towards the VL elimination initiative and that therefore they should receive a similar focus.

- . .

It is made available under a CC-BY-NC-ND 4.0 International license .

77 INTRODUCTION

Visceral Leishmaniasis (VL) - also called *kala-azar* (KA) - is a potentially fatal parasitic disease, caused by Leishmania *donovani* on the Indian subcontinent. Fifteen years after a Memorandum of Understanding was signed by the governments of India, Nepal and Bangladesh committing to its elimination as a public health problem, the goal is on the verge of being achieved. However, with the regional incidence of VL decreasing, understanding the role of potentially highly infectious subgroups in maintaining refractory *Leishmania* transmission is becoming increasingly important.

85 Post kala-azar dermal leishmaniasis (PKDL) is an infectious cutaneous sequel that follows VL in an estimated 5-10% of treated cases in Asia, typically 1-3 years following completion of therapy 86 87 [1, 2]. Because patients with PKDL usually do not have any symptoms other than painless skin 88 lesions, a minority of these patients actively seek medical care, while the condition is often 89 misdiagnosed as leprosy or vitiligo [1, 3]. Untreated PKDL can remain symptomatic for several 90 years [4, 5]. Following the near elimination of VL from the Indian subcontinent in the 1970s, 91 PKDL was suspected to have been the interepidemic reservoir responsible for triggering a new 92 VL outbreak years after the last VL case had been reported in West Bengal [6]. As such PKDL is 93 considered a largely hidden but persistent reservoir of infection, and remains a major threat to the

94 sustainability of the elimination initiative.

95 In Bihar, the most endemic state for VL in India, an estimated 2-7% of VL cases are co-infected 96 with HIV [7-9], although this is most likely an underestimation of the true burden [10]. Data 97 from other settings in the Indian subcontinent are limited, in part due to a lack of routine testing 98 [10]. VL patients co-infected with HIV have been shown to be highly infectious [11]. HIV and 99 leishmaniasis share an immunopathological pathway that enhances replication of both pathogens 100 and accelerates the progression of both VL and HIV [12-14]. A concomitant HIV infection 101 increases the risk of developing active VL by between 100 and 2,320 times [15, 16]. Diagnosing 102 VL in HIV-co-infected patients also poses a major challenge, as VL symptoms are less typical 103 and existing diagnostic tools less accurate [17]. In addition, patients with VL-HIV coinfection 104 experience a lower therapeutic success rate for VL, experience greater drug related toxicity and 105 relapse more frequently than patients not infected with HIV [12, 18, 19]. With each new episode 106 of VL becoming increasingly difficult to treat [20], these patients are likely to remain infectious 107 reservoirs for prolonged periods of time. However, their exact contribution to transmission of VL 108 has yet to be determined.

109 We hypothesized that with the overall decrease in VL cases reported in the Indian subcontinent,

110 PKDL and VL-HIV cases act as important reservoirs of *leishmania* transmission. We therefore

111 investigated to what extent the presence of patients with PKDL or VL-HIV is associated with VL

112 incidence at the village level in Bihar, India.

It is made available under a CC-BY-NC-ND 4.0 International license .

113 METHODS

114 Study site

The state of Bihar is located in northern India and is characterized by a very dense population of 115 116 approximately 120 million, of which over a third live below the poverty line [21]. In 2019, Bihar 117 reported 77% of all VL cases in India [22]. At the same time it carries the second highest 118 number of new HIV infections in the country, and is one of the seven Indian states where 119 reported AIDS related deaths continue to rise [23]. Estimates of the proportion of reported VL 120 patients co-infected with HIV in Bihar state are between 2-7%, although in districts where 121 reliable HIV screening was present up to 20% of adults diagnosed with VL were HIV positive 122 [9, 10]. Six districts within Bihar state were selected for this study on the basis of having the 123 highest VL burden and being geographically contiguous; Darbhanga, Muzaffarpur, Samastipur, 124 Saran, Siwan, and Vaishali (Figure 1).

125 Data sources

126 Routinely collected program data – including the date of diagnosis and the village of residence -127 on incident VL, PKDL and VL-HIV coinfected cases between January 2014 and December 2019 128 were collected for the six selected districts. These data were retrieved through the Kala-azar 129 Management Information System (KAMIS) – an online reporting tool centralizing case reports 130 of leishmaniasis from all VL endemic states within India - with permission of the National 131 Vector Borne Disease Control Program (NVBDCP), India. The national 2011 population census 132 was used as a basis for the population size per village, and adapted to a 2.5% population growth 133 per year. A village level spatial GIS dataset for these districts was made available through the

134 KalaCORE consortium.

135 Data cleaning

136 The initial database included data on 7,886 patients. Double entries – identified based on date of 137 diagnosis, sex, age, and place of residence - were removed from the database, as were patients 138 for whom the village of residence could not be matched with any of the villages available 139 through the census dataset. VL patients for whom no HIV test result was recorded (n = 2,287) 140 were assumed to be HIV negative. 2,357 villages with less than 1,000 inhabitants were attributed 141 to the nearest larger village, using the 'distance matrix' module in Quantum Geographical 142 Information Systems (QGIS). One block (= subdistrict) with no reported cases of VL during the 143 study period was considered to be non-endemic for leishmaniasis and was therefore excluded 144 from the analysis. None of the villages (agglomerates) with a population > 50,000 (n = 9) 145 reported any VL cases; they were therefore excluded from further analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .

147 Statistical analysis

- 148 Data analysis was performed with Stata 14 [StataCorp, Texas, USA]. In a first step we assessed
- 149 whether VL incidence in a village differed by the presence or absence of VL-HIV or PKDL
- 150 cases. For this we calculated the mean VL incidence in villages with and without:
- 151 a) HIV-VL cases in the same year,
- 152 b) PKDL cases in the same year,
- 153 c) HIV-VL cases in the previous year, and
- d) PKDL cases in the previous year, and compared both values using Kruskal-Wallis test (non-normal distribution).
- 156 In a next step, we assessed to what extent presence of VL-HIV or PKDL cases was associated
- 157 with VL incidence at village level, by building a multivariate model using negative binomial
- 158 regression. The VL-HIV cases themselves were excluded from the outcome variable (VL
- 159 incidence). As PKDL can be both cause and effect of VL, we evaluated PKDL in the previous
- 160 year as a potential predictor for VL incidence (instead of PKDL in the same year). Year of
- 161 reporting and block (= subdistrict) were assessed as potential confounders, block as random
- 162 effect and year as fixed effect.

163 *Ethical considerations*

Ethical clearance for this study was obtained from the Institutional Review Board of the Institute of Tropical Medicine, Antwerp, Belgium. The retrospective analysis of routinely collected programme data was supported and approved by the National Vector Borne Disease Control Programme (NVBDCP), Ministry of Health and Family Welfare, India.

168

169 **RESULTS**

170 Descriptive statistics

171 A total of 7,497 cases were included in the analysis; 6,515 cases of VL, 397 cases of VL-HIV,

and 585 cases of PKDL. 5.7% (397/6,909) of all VL cases were co-infected with HIV at the time

173 of diagnosis. 37.8% (2,247/5,938) of the included villages reported ≥ 1 case of VL during the

study period; while 5.4% (322/5,938) and 7.3% (434/5,938) of the villages reported ≥ 1 HIV-VL

175 case and \geq 1 PKDL case respectively. Exact distribution of VL, VL-HIV and PKDL cases per

- 176 year and per district is graphically represented in Figure 2; underlying numbers are available in
- 177 S1 Table and S2 Table.
- 178

It is made available under a CC-BY-NC-ND 4.0 International license .

179 Comparison of VL incidence at village level

180 The overall mean annual VL incidence of all villages between 2014-2019 was 0.59/10,000 181 population per year. The mean annual VL incidence rate was significantly higher in villages with 182 VL-HIV or PKDL cases present in the same or the previous year (Table 1). Cumulative 183 incidence per year and per district can be found in S3 Table and S4 Table.

184 Developing the negative binomial model

185 In the bivariate (unadjusted) analysis, both presence of VL-HIV in the same year and presence of

- 186 PKDL in the previous year were found to be strong predictors for VL incidence at the village
- 187 level, with Incidence Rate Ratios (IRR) of 4.07 (95% CI 2.94 5.63) and 4.63 (95% CI 3.30 –
- 188 6.49) respectively. The year of reporting was identified as a confounder.

189 A multivariate model was then built, with VL incidence as outcome, and the presence of VL-

HIV cases in the same year as well as presence of PKDL cases in the previous year as predictors,

- while controlling for year as a confounder and using block as a random effect to adjust for contextual confounding. The model was further explored by adding an interaction term for VL-
- contextual confounding. The model was further explored by adding an interaction term for VL HIV(same year)*PKDL(previous year), but no interaction was found to be present. Our final
- model can therefore be summarized as follows: VL incidence ~ VL-HIV (same year) + PKDL
- 195 (previous year) + year + block(random effect). In summary, presence of VL-HIV in the same
- 196 year and of PKDL in the previous year both remained strong predictors for VL incidence at
- village level, with an adjusted IRR of 2.16 (95% CI 1.81 2.58) and 2.37 (95% CI 2.01 2.81)
- 198 respectively. Results of the bivariate (unadjusted) and multivariate (adjusted) negative binomial
- 199 regression model can be found in Table 2.

200 Sensitivity analysis

A sensitivity analysis was done fitting the final multivariate negative binomial model for each of the districts separately. As shown in Figure 3, this consistently showed an increased VL

incidence in the presence of current VL-HIV cases or PKDL cases in the previous year in all
 districts, though for PKDL this difference was not significant in one district (underlying numbers
 and confidence intervals are detailed in S5 Table).

206

207 **DISCUSSION**

208 This study suggests that presence of either VL-HIV or PKDL patients is associated with a greater 209 than twofold increase in VL incidence at village level (IRR 2.16 and 2.37 for VL-HIV and 210 PKDL respectively). A similar effect of VL-HIV and PKDL was found in all six districts; though 211 not statistically significant in all, demonstrating a consistent trend supports causality as an 212 explanation. Although the case for focus on PKDL identification and treatment is widely 213 accepted as an important strategy in achieving sustainable elimination [1], these findings indicate 214 the importance of VL-HIV patients as infectious reservoirs, and that a lack of equivalent focus 215 on this cohort may represent a similar level of threat to the VL elimination initiative on the 216 Indian subcontinent. 217

It is made available under a CC-BY-NC-ND 4.0 International license .

This is the first study that attempts to quantify the impact of VL-HIV on population-level transmission within endemic areas. The main strength of this analysis is that our model takes into account the chronological hierarchy between VL and PKDL, excluding as a predictor the PKDL cases which might have developed in a VL case reported earlier in the same year, which would artificially have increased the association.

223 There are a number of limitations in this study. Routinely collected programme data will likely 224 be an underestimation of the real disease burden, not only of VL but also of VL-HIV co-225 infections and PKDL, the latter two of which are difficult to identify. Despite active case finding 226 and numerous information, education and communication (IEC) initiatives implemented as part 227 of the elimination strategy, PKDL patients tend not to seek medical care unless for cosmetic 228 reasons, as they do not feel unwell. Simultaneously, the recommendation for routine testing for 229 HIV of all patients diagnosed with VL in India was only made in 2014, and has taken time to be 230 implemented. Meanwhile, there is no routine screening for VL in patients with HIV living in VL 231 endemic areas in India, despite national recommendations, primarily because of the lack of tools 232 to enable this [9].

Additionally, in the analysis, VL patients for whom no HIV test result was recorded were assumed to be HIV negative. Zero reporting of results in health care surveillance systems remains uncommon, so although this assumption will most likely be correct for most of the patients, some VL cases may have been incorrectly considered as HIV negative.

237 Both PKDL and VL-HIV patients have been shown to be infectious through xenodiagnosis, a 238 procedure in which a vector is allowed to feed on a host in order to verify whether or not they get 239 infected. A recent study from Bangladesh showed that PKDL is only slightly less infectious than 240 VL, with 57% of PKDL patients infecting at least one sand fly compared to 67% of VL patients 241 [24]. Through the same technique, patients with VL-HIV have also been shown to be highly 242 infectious, with even asymptomatic cases infecting vectors, albeit with a different *leishmania* 243 species and in a different context [25, 26]. However no such study on VL-HIV patients has been 244 published on the Indian subcontinent.

245 Evidence on the relative contributions of PKDL and VL-HIV to the transmission of *leishmania* is 246 still evolving. While a 2016 longitudinal study from India reported no evidence of increased 247 transmission in households with PKDL patients over an 18-month follow-up period compared to 248 control households [27], mathematical modeling suggests an increasingly important role for 249 PKDL in the years to come [28]. VL-HIV cases on the other hand are traditionally not included 250 in mathematical models, and the results of this study suggest that this be an important area of 251 consideration for modelers. While the necessity to include PKDL in the elimination efforts has 252 by now been widely accepted, this study suggests that the VL-HIV reservoir warrants an 253 equivalent focus in operational strategies if sustainable elimination is to be achieved. The results 254 of this study would *a-priori* also support the recent recommendation of the use of LLINs in patients diagnosed with PKDL and VL-HIV from the 7th WHO-SEARO Regional Technical 255 256 Advisory Group for Kala Azar.

There remain major gaps in the diagnosis and management of both PKDL and VL-HIV in the Indian subcontinent. PKDL remains for the most part a clinical diagnosis, with the potential for

It is made available under a CC-BY-NC-ND 4.0 International license .

259 mis-identification and missed treatment remaining a major issue. Meanwhile, treatment of PKDL 260 remains challenging, with a 12-week course of oral Miltefosine, a teratogenic oral drug with poor 261 compliance and significant side effects, being the only currently recommended treatment [29]. 262 Meanwhile, there remains little evidence on the sensitivity or specificity of existing non-invasive tests for VL in HIV patients, and considering the case definition of VL remains the same for co-263 264 infected and immunocompetent patients, it is likely that a substantial number of co-infected 265 patients are missed. In addition, management of co-infected patients remains fraught with 266 challenges [10, 30]. New tools and strategies are urgently required to improve case detection and management of both entities to reduce their infectious potential. This will both improve the 267 268 chances, and indeed capitalize on the substantial investment, of sustainable elimination in the 269 subcontinent.

270 *Conflict of interest*

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

273 Author contributions

EH, SB, PM, and KC contributed to the conception and design of the study. Data curation was
performed by NG, PM and EH. Formal analysis was performed by PM and KC and validated by
SB and EH. Writing of the original draft manuscript was performed by PM and KC. All authors
contributed to manuscript revision, read, and approved the submitted version.

278 Data availability

279 Data cannot be shared publicly by the researchers as they are property of the National Vector

280 Borne Disease Control Programme (NVBDCP) of India. They are available to others on

281 condition of request and approval of the NVBDCP (contact via nareshgill.nvbdcp@yahoo.com).

- 283
- 284 285
- 286
- 287
- 288
- 289
- 290
- 291
- 292 293
- 294
- 295
- 296
- 297
- 298

It is made available under a CC-BY-NC-ND 4.0 International license .

299 FIGURES AND TABLES

300 Figure captions

- **Figure 1 :** Geographical location of the six study districts within Bihar state, India.
- 302 **Figure 2 :** Number of VL, VL-HIV, and PKDL cases reported per year and per district.
- **Figure 3 :** Tornado chart graphically representing the results of the sensitivity analysis of the
- 304 final model for the different districts. On the horizontal axis, the adjusted Incidence Rate Ratio is
- 305 displayed for VL-HIV in the same year and PKDL in the previous year respectively.

306 *Tables*

307 Table 1 : Mean VL incidence per 10,000 population per year, comparing villages with and

308 without presence of VL-HIV or PKDL cases in the same or the previous year. The reported p-309 value was calculated using Kruskal Wallis chi square test (non-normal distribution).

		, .	0
	present (SD)	absent (SD)	p-value χ2
HIV-VL in the same year	2.32 (5.70)	0.58 (2.77)	0.0001
PKDL in the same year	4.98 (9.98)	0.53 (2.54)	0.0001
HIV-VL in the previous year	1.70 (4.70)	0.68 (3.10)	0.0001
PKDL in the previous year	2.67 (5.68)	0.67 (3.07)	0.0001

Mean VL incidence/10,000/year on village level

310

311 Table 2 : Results of bivariate (crude) and multivariate (adjusted) analysis using negative 312 binomial regression. Incidence rate ratios (IRR) for VL are presented, including 95% confidence 313 intervals (95% CI) and p-values. Statistically significant associations (p-values <0.05) are 314 highlighted in bold.

- 315
- 316

		Crude		Adjusted			
		IRR	95% CI	P-value	IRR	95% CI	P-value
Presence of VL-HIV in	No	Ref.			Ref.		
the same village in the same year	Yes	4.07	(2.94 – 5.63)	<0.001	2.16	(1.81 – 2.58)	<0.001
Presence of PKDL in	No	Ref.			Ref.		
the same village in the previous year	Yes	4.63	(3.30 – 6.49)	<0.001	2.37	(2.01 – 2.81)	<0.001
Interaction term VL-							
HIV(same		NA					0.795
year)*PKDL(previous							

It is made available under a CC-BY-NC-ND 4.0 International license .

year)	

317

318 REFERENCES

319	
320	1. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in the
321	Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
322	PLoS neglected tropical diseases. 2017;11(11):e0005877.
323	2. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal
324	leishmaniasis. Lancet Infect Dis. 2003;3(2):87-98.
325	3. Ramesh V, Kaushal H, Mishra AK, Singh R, Salotra P. Clinico-epidemiological analysis
326	of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital
327	based retrospective study. BMC Public Health. 2015;15:1092.
328	4. Das AK, Harries AD, Hinderaker SG, Zachariah R, Ahmed B, Shah GN, et al. Active and
329	passive case detection strategies for the control of leishmaniasis in Bangladesh. Public Health
330	Action. 2014;4(1):15-21.
331	5. Garapati P, Pal B, Siddiqui NA, Bimal S, Das P, Murti K, et al. Knowledge, stigma,
332	health seeking behaviour and its determinants among patients with post kalaazar dermal
333	leishmaniasis, Bihar, India. PloS one. 2018;13(9):e0203407.
334	6. Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar
335	dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ.
336	1992;70(3):341-6.
337	7. Mathur P, Samantaray JC, Vajpayee M, Samanta P. Visceral leishmaniasis/human
338	immunodeficiency virus co-infection in India: the focus of two epidemics. J Med Microbiol.
339	2006;55(Pt 7):919-22.
340	8. Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, et al. HIV and visceral
341	leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against
342	elimination. Clinical infectious diseases : an official publication of the Infectious Diseases
343	Society of America. 2014;59(4):552-5.
344	9. Directorate National Vector Borne Disease Control Programme India. Accelerated plan
345	for Kala-azar elimination 2017 [Available from:
346	https://nvbdcp.gov.in/WriteReadData/1892s/Accelerated-Plan-Kala-azar1-Feb2017.pdf]
347	(accessed May 10, 2020).
348	10. Akuffo H, Costa C, van Griensven J, Burza S, Moreno J, Herrero M. New insights into
349	leishmaniasis in the immunosuppressed. PLoS neglected tropical diseases. 2018;12(5):e0006375.
350	11. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Annals of
351	tropical medicine and parasitology. 2003;97 Suppl 1:29-45.
352	12. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship
353	between leishmaniasis and AIDS: the second 10 years. Clinical microbiology reviews.
354	2008;21(2):334-59.
355	13. Tremblay M, Olivier M, Bernier R. Leishmania and the pathogenesis of HIV infection.
356	Parasitology today (Personal ed). 1996;12(7):257-61.
357	14. Mock DJ, Hollenbaugh JA, Daddacha W, Overstreet MG, Lazarski CA, Fowell DJ, et al.
358	Leishmania induces survival, proliferation and elevated cellular dNTP levels in human
359	monocytes promoting acceleration of HIV co-infection. PLoS pathogens. 2012;8(4):e1002635.

360 15. Lopez-Velez RP-MJAGABFVJELBCP-CFAJ. Clinicoepidemiologic characteristics, 361 prognostic factors, and survival analysis of patients coinfected with human immunodeficiency 362 virus and leishmania in an area of Madrid, Spain. 1998. 363 16. World Health Organization. Leishmaniasis and HIV coinfection [Available from: 364 https://www.who.int/leishmaniasis/burden/hiv coinfection/burden hiv coinfection/en/] 365 (accessed April 7, 2020). 366 Singh S. Changing trends in the epidemiology, clinical presentation, and diagnosis of 17. 367 Leishmania-HIV co-infection in India. International journal of infectious diseases : IJID : official 368 publication of the International Society for Infectious Diseases. 2014;29:103-12. 369 18. Cota GF, de Sousa MR, Rabello A. Predictors of Visceral Leishmaniasis Relapse in HIV-370 Infected Patients: A Systematic Review. PLoS neglected tropical diseases. 2011;5(6):e1153. 371 Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, et al. Visceral 19. 372 Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment 373 Outcomes with Liposomal Amphotericin B (AmBisome). PLoS neglected tropical diseases. 374 2014:8(8):e3053. 375 20. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in 376 immunosuppressed individuals. Clinical microbiology and infection : the official publication of 377 the European Society of Clinical Microbiology and Infectious Diseases. 2014;20(4):286-99. 378 The World Bank. Bihar Poverty, Growth and Inequality. 2016 [Available from: 21. 379 http://documents.worldbank.org/curated/en/781181467989480762/pdf/105842-BRI-P157572-380 PUBLIC-Bihar-Proverty.pdf] (accessed May 20, 2020). 381 22. National Vector Borne Disease Control Programme I. National Vector Borne Disease 382 Control Programme, India. Kala-azar Cases and Deaths in the country since 2013. [Available 383 from: https://nvbdcp.gov.in/index4.php?lang=1&level=0&linkid=467&lid=3750] (accessed 384 March 23, 2020). 385 23. National AIDS Control Organization, India. India HIV estimations 2017 - fact sheets 386 [Available from: 387 http://naco.gov.in/sites/default/files/HIV%20Estimations%202017%20Report 1.pdf] (accessed 388 April 5, 2020). 389 Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying the 24. 390 Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies. Clinical infectious 391 diseases : an official publication of the Infectious Diseases Society of America. 2019;69(2):251-392 8. 393 25. Molina R, Lohse JM, Pulido F, Laguna F, López-Vélez R, Alvar J. Infection of sand flies 394 by humans coinfected with Leishmania infantum and human immunodeficiency virus. The 395 American journal of tropical medicine and hygiene. 1999;60(1):51-3. 396 Ferreira GR, Castelo Branco Ribeiro JC, Meneses Filho A, de Jesus Cardoso Farias 26. 397 Pereira T, Parente DM, Pereira HF, et al. Human Competence to Transmit Leishmania infantum 398 to Lutzomyia longipalpis and the Influence of Human Immunodeficiency Virus Infection. The 399 American journal of tropical medicine and hygiene. 2018;98(1):126-33. 400 Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, et al. 27. 401 Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic 402 Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS neglected tropical 403 diseases. 2016;10(12):e0005196. 404 28. Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-Azar Dermal Leishmaniasis as a 405 Reservoir for Visceral Leishmaniasis Transmission. Trends in parasitology. 2019;35(8):590-2.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 406 29. Pijpers J, den Boer ML, Essink DR, Ritmeijer K. The safety and efficacy of miltefosine
 407 in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia A review and
- 408 meta-analysis. PLoS neglected tropical diseases. 2019;13(2):e0007173.
- 409 30. Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in
- 410 visceral leishmaniasis among HIV infected patients: a systematic review with indirect
- 411 comparison. PLoS neglected tropical diseases. 2013;7(5):e2195.





